Product Information
LANSOPRAZOLE DR 30 MG CAPSULE is a generic product labeled by Camber Pharmaceuticals Inc., priced at $0.1061 per EA under NDC 31722057105. Its NADAC has been published 270 times since Aug 4, 2021.
FDA first approved this application on May 18, 2020. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
30 mg/1
Manufacturer
Camber Pharmaceuticals Inc.NDC
31722057105
Classification
Generic
Dosage Form
CAPSULE, DELAYED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
LANSOPRAZOLEApproval Type
Generic (ANDA)
FDA Application
ANDA203083FDA Approved
5/18/2020
TE Code
AB
On Market Since
5/18/2020
Pharmacological Classes
Price Statistics
The NADAC for LANSOPRAZOLE DR 30 MG CAPSULE has been published 270 times since Aug 4, 2021, and over the history we have for it it has declined 32.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1061 per EA |
|---|---|
| All-time high | $0.1646 (Nov 10, 2021) |
| All-time low | $0.0754 (Nov 20, 2024) |
| 52-week high | $0.1089 |
| 52-week low | $0.1049 |
| Median price | $0.1089 |
| Average price | $0.1122 |
| Largest weekly change | -28.6% (Nov 20, 2024) |
| Weeks tracked | 270 |
| Tracking since | Aug 4, 2021 |
Generic Alternatives
The matcher finds 7 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Camber Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Lansoprazole market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Proton Pump Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LANSOPRAZOLE DR 30 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for LANSOPRAZOLE DR 30 MG CAPSULE, manufactured by Camber Pharmaceuticals Inc., is $0.1061 per EA (NDC 31722057105), effective Sep 30, 2026.
How has the price of LANSOPRAZOLE DR 30 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for LANSOPRAZOLE DR 30 MG CAPSULE has declined 32.4%. It has been tracked across 270 weekly CMS publications since Aug 4, 2021.
What are the highest and lowest recorded NADAC prices for LANSOPRAZOLE DR 30 MG CAPSULE?
Since Aug 4, 2021, the NADAC for LANSOPRAZOLE DR 30 MG CAPSULE has ranged from a low of $0.0754 (Nov 20, 2024) to a high of $0.1646 (Nov 10, 2021), with a median of $0.1089 per EA.
Are there cheaper alternatives to LANSOPRAZOLE DR 30 MG CAPSULE?
7 manufacturers publish a NADAC-priced product with the same active ingredient and strength as LANSOPRAZOLE DR 30 MG CAPSULE in a comparable dosage form, but none are currently priced below it.
Who manufactures LANSOPRAZOLE DR 30 MG CAPSULE?
LANSOPRAZOLE DR 30 MG CAPSULE (NDC 31722057105) is labeled by Camber Pharmaceuticals Inc., and CMS classifies it as a generic product.